ZA981080B - Bicyclic inhibitors of protein farnesyl transferase - Google Patents

Bicyclic inhibitors of protein farnesyl transferase

Info

Publication number
ZA981080B
ZA981080B ZA981080A ZA981080A ZA981080B ZA 981080 B ZA981080 B ZA 981080B ZA 981080 A ZA981080 A ZA 981080A ZA 981080 A ZA981080 A ZA 981080A ZA 981080 B ZA981080 B ZA 981080B
Authority
ZA
South Africa
Prior art keywords
pct
farnesyl transferase
present
protein farnesyl
date aug
Prior art date
Application number
ZA981080A
Other languages
English (en)
Inventor
Ellen M Dobrusin
Dennis Joseph Mcnamara
Matthew Drowns
James Stanley Kaltenbronn
Joseph Thomas Repine
Annette Marian Doherty
Jack Bikker
Marcin Stasiak
Quinn John Iii
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA981080B publication Critical patent/ZA981080B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA981080A 1997-02-11 1998-02-10 Bicyclic inhibitors of protein farnesyl transferase ZA981080B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3750497P 1997-02-11 1997-02-11

Publications (1)

Publication Number Publication Date
ZA981080B true ZA981080B (en) 1998-08-12

Family

ID=21894697

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA981080A ZA981080B (en) 1997-02-11 1998-02-10 Bicyclic inhibitors of protein farnesyl transferase

Country Status (13)

Country Link
US (3) US6133303A (xx)
EP (1) EP0966446B1 (xx)
JP (1) JP2001518076A (xx)
KR (1) KR20000070924A (xx)
AT (1) ATE307119T1 (xx)
AU (1) AU725696B2 (xx)
BR (1) BR9807674A (xx)
CA (1) CA2273895A1 (xx)
DE (1) DE69831937T2 (xx)
ES (1) ES2252827T3 (xx)
NZ (1) NZ336134A (xx)
WO (1) WO1998034921A1 (xx)
ZA (1) ZA981080B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2001253601A1 (en) * 2000-04-17 2001-10-30 Warner Lambert Company 5-substituted tetralones as inhibitors of ras farnesyl transferase
AU2001251649A1 (en) * 2000-04-17 2001-10-30 Warner Lambert Company Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20060004001A1 (en) * 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
US7550482B2 (en) * 2004-02-27 2009-06-23 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
CA2730280A1 (en) * 2008-07-10 2010-01-14 Southern Research Institute 5-quinolinone and imidazopyridine compounds and use thereof
US8725967B2 (en) * 2008-08-08 2014-05-13 Amazon Technologies, Inc. Providing executing programs with access to stored block data of others
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
PT3041507T (pt) 2013-08-26 2021-07-26 Biontech Res And Development Inc Ácidos nucleicos que codificam anticorpos humanos para sialil-lewis
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
HUE055189T2 (hu) 2014-06-04 2021-11-29 Biontech Res And Development Inc Humán monoklonális antitestek a GD2 ganglioziddal ellen
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN105801421A (zh) * 2016-03-31 2016-07-27 常州大学 一种2-醛基-3-羟基-4,6-二氯苯甲酸的合成方法
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535225A (de) * 1969-03-29 1973-03-31 Schering Ag Verfahren zur Herstellung von heterocyclischen Nitroverbindungen
DE1937630A1 (de) * 1969-07-19 1971-02-04 Schering Ag 2-(5-Nitro-2-furfuryliden)-l-tetralone
JPS6013788A (ja) * 1983-07-05 1985-01-24 Yamanouchi Pharmaceut Co Ltd 新規なクマリン誘導体
BR8305086A (pt) 1983-09-19 1984-03-20 Antonio Signori Dispositivo de amortecimento aplicavel a calcados em geral
ES8601148A1 (es) * 1984-12-10 1985-11-16 Ferrer Int Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos.
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
US5149703A (en) * 1991-09-06 1992-09-22 Merck Frosst Canada, Inc. Quinoline-substituted chromans and related compounds as leukotriene antagonists
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
CZ100095A3 (en) * 1992-10-21 1995-11-15 Pfizer Sulfonamide derivatives of hydroxy substituted alicyclic or heterocyclic compounds with condensed benzene nucleus and pharmaceutical preparations based thereon
JPH10510510A (ja) * 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
EP0695753A1 (en) * 1994-08-05 1996-02-07 Zeneca Limited Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
WO1997017070A1 (en) * 1995-11-06 1997-05-15 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6090948A (en) * 1996-01-30 2000-07-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507589A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6410539B1 (en) * 1997-10-22 2002-06-25 Astrazenca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
FR2787451B1 (fr) * 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
US6403581B1 (en) * 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives

Also Published As

Publication number Publication date
ATE307119T1 (de) 2005-11-15
US6528535B2 (en) 2003-03-04
KR20000070924A (ko) 2000-11-25
JP2001518076A (ja) 2001-10-09
US20020006936A1 (en) 2002-01-17
AU6170498A (en) 1998-08-26
BR9807674A (pt) 2000-02-15
DE69831937T2 (de) 2006-07-27
US6265422B1 (en) 2001-07-24
WO1998034921A1 (en) 1998-08-13
CA2273895A1 (en) 1998-08-13
EP0966446B1 (en) 2005-10-19
US6133303A (en) 2000-10-17
EP0966446A1 (en) 1999-12-29
AU725696B2 (en) 2000-10-19
NZ336134A (en) 2001-08-31
DE69831937D1 (de) 2006-03-02
ES2252827T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
ZA981080B (en) Bicyclic inhibitors of protein farnesyl transferase
EP0762879A4 (en) STEREOCHEMICAL WORDMAN DERIVATIVES
NZ294933A (en) Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents
CA2322944A1 (en) Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
UA29446C2 (uk) Засіб для інгібування тромбіну
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
MX9800411A (es) Compuestos quimicos.
MY120090A (en) Chemical compounds.
GR3030354T3 (en) Substituted arylalkynyl- and heteroarylalkynyl-n-hydroxyurea inhibitors of leukotriene biosynthesis.
GR3017996T3 (en) 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION.
NO996578L (no) Urokinase-inhibitorer
AU5320698A (en) Substituted dihydrobenzofurans as pde inhibitors
EP0646007A4 (xx)
MX9602861A (es) Mezcla estabilizante sinergistica.
GB9712966D0 (en) Novel chalcones
AU9066498A (en) Substituted 6-alkylphenanthridines
DE69713524D1 (en) 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative
BG103553A (en) Benzopyranopyrol and benzopyranopyridine alpha-1 adrenergic compounds
PL331347A1 (en) Derivatives of n-benzene sulphonyl-l-proline
HU9501777D0 (en) Method of treatment of chronic prostatitis with 17-beta-monosubstituted-carbamoly-4-aza-5-alpha-androst-1-en-3-ones
AP2000001859A0 (en) Method for treating multiple sclerosis
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
PL318539A1 (en) Inhibition of biosynthesis
PL317538A1 (en) Intermediate compound for obtaining a pharmaceutically active compound